Seres Therapeutics Announces Microbiome Immuno-Oncology Focused Collaboration with AstraZeneca
- Collaboration focused on further elucidating the potential of microbiome therapeutics to augment immuno-oncology treatment for cancer –
- Seres to receive
- Company to further discuss collaboration during webcast Cowen
healthcare conference presentation scheduled for
Preclinical and early clinical evidence suggests that the composition of the gastrointestinal microbiome impacts clinical response to checkpoint inhibitor immunotherapy and supports the hypothesis that modification of the microbiome may improve outcomes. These data provide strong support for continued research to further understand the microbiome as a predictor of response to checkpoint inhibitors and to elucidate the potential of microbiome therapeutics to augment immunotherapy.
Under the collaboration, research will evaluate microbiome-based
approaches as a predictor for which patients may respond best to certain
cancer immunotherapies. Additionally, SER-401, an investigational
microbiome therapeutic, may be studied in combination with
“We are very pleased to be collaborating with
“Our new collaboration with
Under the terms of the exclusive collaboration,
About Seres Therapeutics
About SER-401
SER-401 is an oral microbiome therapeutic candidate sourced from
screened healthy individuals who have been identified to have a
microbiome bacterial signature similar to that observed in responders to
cancer immunotherapy. The therapeutic aim of SER-401 is to modify the
microbiome of cancer patients to increase the efficacy of immunotherapy.
SER-401 is being evaluated in a Phase 1b clinical study being conducted
in collaboration with
Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including expectations regarding future payments, the ability of microbiome therapeutics to impact the response to cancer immunotherapy, and any possible benefits from the collaboration.
These forward-looking statements are based on management’s current
expectations. These statements are neither promises nor guarantees, but
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements,
including, but not limited to, the following: we have incurred
significant losses, are not currently profitable and may never become
profitable; our need for additional funding; our limited operating
history; our unproven approach to therapeutic intervention; the lengthy,
expensive, and uncertain process of clinical drug development; our
reliance on third parties and collaborators to conduct our clinical
trials, manufacture our product candidates, and develop and
commercialize our product candidates, if approved; the success of our
leadership transition; our ability to retain key personnel and to manage
our growth; and our management and principal stockholders have the
ability to control or significantly influence our business. These and
other important factors discussed under the caption “Risk Factors” in
our Annual Report on Form 10-K filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20190311005498/en/
Source:
IR and PR Contact:
Carlo Tanzi, Ph.D., Seres Therapeutics,
617-203-3467
Vice President, Investor Relations and Corporate
Communications
ctanzi@serestherapeutics.com